Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for FLT3-mutated acute myeloid leukaemia, drawn from the whole corpus: 10 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Which FLT3 inhibitor to pair with intensive chemotherapy, and whether one inhibitor suits both ITD and TKD disease.
Whether post-transplant maintenance should be given to everyone or only to patients with detectable FLT3-ITD.
Resistance through FLT3 gatekeeper mutations and through loss of FLT3 dependence.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 15 changes by month →When this page itself was last checked or edited.
Relapse-free survival hazard ratio 0.
Frontline FLT3-ITD AML (QuANTUM-First)
Newly diagnosed FLT3-ITD AML with 7+3, consolidation, and maintenance
A milestone in how this cancer is treated.
OS 31.